Takeda's Investigational Compound SYR-322 for Treatment of Diabetes Enters US Phase 3 Clinical Stage.Tokyo, Japan, Jan 20, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical announced today that its investigational compound SYR-322 has entered into Phase 3 clinical stage. SYR-322 is one of the DPP DPP - Dining Philosophers Problem 4 inhibitors for the treatment of type 2 diabetes type 2 diabetes n. See diabetes mellitus. discovered by one of Takeda's subsidiaries in the US, Takeda San Diego, Inc. The Phase 3 studies are to be conducted globally through Takeda Global Research & Development Center Inc. using the contract research services of PPD (1) (Parallel Presence Detect) The method used by earlier SIMM memory modules to communicate their capacity to the computer. A binary number coming from a parallel set of pins was read by the system, with each pin representing one bit. Contrast with SPD. , Inc. (Wilmington, N.C.). DPP4 inhibitors, taken orally, block the degradation of GLP-1 (Glucagon-like peptide-1), and help to maintain the concentration of GLP-1 in blood for a longer period of time. GLP-1 stimulates pancreatic beta cells beta cells, n See cells, beta. to increase the secretion of insulin, so GLP-1 has the potential to improve beta cell function itself. Thus, DPP4 inhibitors may represent a new generation of oral agents for diabetes treatment. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion